Myelos: Reversing neurologic damage

While most treatments for neurodegenerative diseases attempt to prevent disease or stave off disease progression, they are unable to reverse and repair damage caused by neurological disorders. Myelos Neurosciences Corp. is developing Prosaptide TX14(A), its lead compound, and second generation derivatives that the company says not only prevent neuronal death but also induce neuronal regeneration.

Work at the University of California at San Diego led to the identification of stimulatory sequences within neurotrophic factors and other growth factors. Company founder John O'Brien, professor of neurosciences at UCSD and discoverer of the primary enzyme deficiency of Tay-Sachs disease, created Myelos to commercialize these early discoveries. Myelos holds an exclusive license to the university technology for developing peptides that mimic the stimulatory sequences to treat neurologic disorders...